A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

Last updated: April 18, 2025
Sponsor: Vertex Pharmaceuticals Incorporated
Overall Status: Active - Recruiting

Phase

4

Condition

Acute Pain

Pain

Treatment

Suzetrigine

Clinical Study ID

NCT06887972
VX24-548-113
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study to evaluate the effectiveness, safety, and tolerability of SUZ as part of multimodal therapy (MMT) in treating acute postoperative pain.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  • Body mass index (BMI) of greater than or equal to (≥)18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m^2)

  • Participants scheduled to undergo an aesthetic or reconstructive surgical procedurethat would typically be treated with opioid therapy for at least 72 hourspostoperatively

Exclusion

Key Exclusion Criteria:

• Participated in a previous study with SUZ or received Journavx

Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Suzetrigine
Phase: 4
Study Start date:
March 21, 2025
Estimated Completion Date:
January 01, 2026

Connect with a study center

  • Atlanta Center for Medical Research

    Atlanta, Georgia 30331
    United States

    Active - Recruiting

  • HD Research LLC | First Surgical Hospital

    Bellaire, Texas 77401
    United States

    Active - Recruiting

  • Memorial Hermann Village

    Houston, Texas 77043
    United States

    Active - Recruiting

  • JBR Clinical Research

    Salt Lake City, Utah 84107
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.